Onco-Blockbuster: GSK to Acquire Nuvalent in Milestone $10.6 Billion Cash Takeover

In its largest corporate transaction in over a decade, British pharma titan GSK launches an all-cash takeover of Nuvalent to capture an elite portfolio of next-generation lung cancer treatments.










